Eli Lilly’s Retatrutide Sets New Weight-Loss Records in Phase 3 Trials

Key points

• Retatrutide is a triple-agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly.
• In the TRIUMPH-1 trial (obesity, no diabetes), the highest dose resulted in an average 25% weight loss over 80 weeks, reaching 30% after 104 weeks.
• In the TRIUMPH-2 trial (obesity with type 2 diabetes), the highest dose led to an average 23% weight loss (49.6 pounds) over 80 weeks.
• The drug significantly reduced knee pain, sleep apnea events, and improved blood pressure, cholesterol, and blood sugar levels.
• Side effects were primarily gastrointestinal, including nausea and diarrhea, with seven unrelated deaths reported in the diabetes trial.
• Eli Lilly plans to submit for FDA approval early next year, but unauthorized versions are already being sold via compounding pharmacies.

Background

Retatrutide follows the success of GLP-1 agonists like semaglutide (Ozempic/Wegovy) and dual-agonists like tirzepatide (Mounjaro/Zepbound). Previous archive coverage noted that while these drugs offer significant benefits, they carry risks such as muscle loss and potential mood changes. Retatrutide represents the next generation, aiming for efficacy comparable to bariatric surgery without the surgical risks.

How outlets are covering it

Ars Technica emphasizes the drug’s unprecedented efficacy, noting that over a third of participants lost 30% or more of their weight, and highlights the lack of head-to-head comparisons with tirzepatide. The Guardian focuses on the broader health benefits, including reduced inflammation and improved cardiometabolic risk factors, while noting the drug’s potential to resolve type 2 diabetes. NBC News highlights the dramatic weight loss figures, comparing them to bariatric surgery, and raises concerns about the drug’s intensity for patients with mild conditions. Scientific American frames the results as a 'new high-water mark' for the field, noting that people with type 2 diabetes typically lose less weight on GLP-1 drugs, making these results particularly significant. All sources agree on the drug’s potential but differ in their emphasis on side effects and accessibility concerns.

Why it matters

Retatrutide’s success could redefine the treatment landscape for obesity and type 2 diabetes, offering a non-surgical option with efficacy rivaling bariatric surgery. Its potential to resolve prediabetes and improve cardiometabolic markers could have significant public health implications. However, the lack of head-to-head comparisons and the presence of side effects raise questions about its optimal use and safety profile.

What to watch

Eli Lilly plans to submit retatrutide for FDA approval early next year. Larger, longer trials are needed to assess rare safety risks, such as cardiovascular events and pancreatitis. The drug’s availability and pricing will likely be major points of debate, as unauthorized versions are already being sold through compounding pharmacies.